ALEC | OMER Message Board Posts

Omeros Corporation

  OMER website

OMER   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2808 of 3368  at  2/10/2020 1:55:57 PM  by

smittyfrmpa


ALEC

Despite a clearly different MOA, complement pathway company Alector gets taken down hard, in sympathy with AD failures announced this morning, by Roche and Lilly. Lilly has no relation here, with solanezumab targeting amyloid plaques. The Roche drug, although targeting amyloid plaques, mentions "recruiting" microglia, with microglia central to Alector's MOA. I may re-buy ALEC, right here.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 261
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
2809 Re: ALEC Biotech_Jim 1 2/10/2020 3:04:04 PM






Financial Market Data provided by
.
Loading...